Drug-induced heart failure

American Journal of Health-System Pharmacy

Volumn 68, Issue 19, 2011, Pages 1791-1804

  Maxwell, Carleton B ^a   Jenkins, Antoine T ^b  

^a CAROLINAS MEDICAL CENTER   (United States)

^b CHICAGO STATE UNIVERSITY   (United States)

Author keywords

Antifungals; Antineoplastic agents; Bevacizumab; Cardiac drugs; Dronedarone; Dutasteride; Heart failure; Immunomodulating agents; Itraconazole; Lapatinib; Postmarketing surveillance; Thiazolidinediones; Toxicity; Tyrosine kinase inhibitors

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMIODARONE; ANTHRACYCLINE; ANTIARRHYTHMIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOLOGICAL RESPONSE MODIFIER; CYCLOPHOSPHAMIDE; DISOPYRAMIDE; DOFETILIDE; DOXORUBICIN; DRONEDARONE; EPIRUBICIN; IFOSFAMIDE; IMATINIB; ITRACONAZOLE; LAPATINIB; MITOMYCIN; MITOXANTRONE; NONSTEROID ANTIINFLAMMATORY AGENT; PIOGLITAZONE; PROPAFENONE; PROTEIN TYROSINE KINASE INHIBITOR; ROFECOXIB; ROSIGLITAZONE; SUNITINIB; TOCAINIDE; TRASTUZUMAB; UNINDEXED DRUG;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE EXACERBATION; HEART FAILURE; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; REVIEW; STROKE; SYSTEMATIC REVIEW;

EID: 80053522805     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp100637     Document Type: Review

References (112)

1. Hunt SA, Abraham WT, Chin MH et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005; 112:e154-235.
2. Hunt SA, Abraham WT, Chin MH et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009; 119:e391-479. [Erratum, Circulation. 2010 Mar 30; 121:e258.]
3. Lloyd-Jones D, Adams RJ, Brown TM et al. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation. 2010; 121:e46-215.
4. Adams KF, Lindenfeld J, Arnold JM et al. HFSA 2006 comprehensive heart failure practice guideline. J Card Fail. 2006; 12:e1-122.
5. Jessup M, Abraham WT, Casey DE et al. Writing on behalf of the 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult Writing Committee. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation. 2009; 119:1977-2016.
6. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham Study. JAMA. 1979; 241:2035-8. (Pubitemid 9228506)
7. Kendall DM. Thiazolidinediones: the case for early use. Diabetes Care. 2006; 29:154-7. (Pubitemid 44033452)
8. Patel RR. Thiazolidinediones and congestive heart failure. Cardiol Rev. 2009; 17:132-5.
9. Avandia (rosiglitazone malate) package insert. Research Triangle Park, NC: GlaxoSmithKline; 2009.
10. Actos (pioglitazone hydrochloride) package insert. Deerfield, IL: Takeda Pharmaceuticals America; 2008 Aug.
11. Nesto RW, Bell D, Bonow RO et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from American Heart Association and American Diabetes Association. Circulation. 2003; 108:2941-8. (Pubitemid 37517824)
12. Cheng AY, Fantus G. Thiazolidinedione-induced congestive heart failure. Ann Pharmacother. 2004; 38:817-20. (Pubitemid 38509060)
13. Delea TE, Edelsberg JS, Hagiwara M et al. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes. Diabetes Care. 2003; 26:2983-9. (Pubitemid 37339487)
14. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macro Vascular Events): a randomised controlled trial. Lancet. 2005; 366:1279-89. (Pubitemid 41416583)
15. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) trial investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006; 368:1096-1105. [Erratum, Lancet. 2006; 368:1770.]
16. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356:2457-71. (Pubitemid 46919772)
17. Horne PD, Pocock SJ, Beck-Neilsen H et al. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med. 2007; 357:28-38. (Pubitemid 47026732)
18. Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleoanalysis. Diabetes Care. 2007; 30:2148-53.
19. Winkelmayer WC, Setoguchi S, Levin R et al. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med. 2008; 168:2368-75.
20. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA. 2010; 304:411-8.
21. Food and Drug Administration. FDA drug safety communication: updated risk evaluation and mitigation strategy (REMS) to restrict access to rosiglitazone-containing medicines including Avandia, Avandamet, and Avandaryl. www. fda.gov/drugs/drugsafety/ucm255005.htm (accessed 2011 Jun 21).
22. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf. 2000; 22:263-302. (Pubitemid 30213944)
23. Giantris A, Abdurrahman L, Hinkle A et al. Anthracycline-induced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol. 1998; 27:53-68. (Pubitemid 28275509)
24. Lefrak EA, Pitha J, Rosenheim S et al. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973; 32:302-14.
25. Ryberg M, Nielsen D, Skovsgaard T et al. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol. 1998; 16:3502-8. (Pubitemid 28506760)
26. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003; 97:2869-79. (Pubitemid 36605157)
27. Yeh ET, Tong AT, Lenihan DJ et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004; 109:3122-31.
28. Raschi E, Vasina V, Ursino MG et al. Anticancer drugs and cardiotoxicity:insights and perspectives in the era of targeted therapy. Pharmacol Ther. 2010; 125:196-218.
29. Posner LE, Dukart G, Goldberg J et al. Mitoxantrone: an overview of safety and toxicity. Invest New Drugs. 1985; 3:123-32. (Pubitemid 15005813)
30. Minotti G, Menna P, Salvatorelli E et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004; 56:185-229. (Pubitemid 38720829)
31. Gottdiener JS, Appelbaum FR, Ferrans VJ et al. Cardiotoxicity associated with highdose cyclophosphamide therapy. Arch Intern Med. 1981; 141:758-63. (Pubitemid 11120879)
32. Kupari M, Volin L, Suokas A et al. Cardiac involvement in bone marrow transplantation: electrocardiographic changes, arrhythmias, heart failure and autopsy findings. Bone Marrow Transplant. 1990; 5:91-8. (Pubitemid 20116085)
33. Braverman AC, Antin JH, Plappert MT et al. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol. 1991; 9:1215-23.
34. Sarosy G. Ifosfamide - pharmacologic overview. Semin Oncol. 1989; 16(1, suppl 3):2-8. (Pubitemid 19116950)
35. Quezado ZM, Wilson WH, Cunnion RE et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med. 1993; 118:31-6. (Pubitemid 23007969)
36. Buzdar AU, Legha SS, Tashima CK et al. Adriamycin and mitomycin C: possible synergistic cardiotoxicity. Cancer Treat Rep. 1978; 62:1005-8. (Pubitemid 8405987)
37. Murphy CA, Dargie HJ. Drug-induced cardiovascular disorders. Drug Saf. 2007; 30:783-804. (Pubitemid 47347352)
38. Hudis CA. Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med. 2007; 357:39-51. (Pubitemid 47026733)
39. Guglin M, Hartlage G, Reynolds C et al. Trastuzumab-induced cardiomyopathy: not as benign as it looks? A retrospective study. J Card Fail. 2009; 15:651-7.
40. Ewer MS, Vooletich MT, Durand JB et al. Reversibility of trastuzumab-related cardiomyopathy: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005; 23:7820-6. (Pubitemid 46657379)
41. Herceptin (trastuzumab) package insert. South San Francisco, CA: Genentech; 2010 Oct.
42. Perez EA, Koehler M, Byrne J et al. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 2008; 83:679-86. (Pubitemid 351810568)
43. Tykerb (lapatinib) package insert. Research Triangle Park, NC: GlaxoSmith-Kline; 2010 Apr.
44. Avastin (bevacizumab) package insert. South San Francisco, CA. Genentech; 2011 Feb.
45. Choueiri TK, Mayer EL, Je Y et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol. 2011; 29:632-8.
46. Food and Drug Administration. Avastin (bevacizumab): process for removal of breast cancer indication begun. www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm237280.htm (accessed 2011 May 16).
47. Sutent (sunitinib malate) package insert. New York, NY: Pfizer; 2010 Jul.
48. Chu TF, Rupnick MA, Dallabrida SM et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007; 370:2011-9. (Pubitemid 350236338)
49. Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006; 295:2516-24. (Pubitemid 43854967)
50. Savage DG, Antman KH. Imatinib mesylate - a new oral targeted therapy. N Engl J Med. 2002; 346:683-93. (Pubitemid 34815874)
51. Atallah E, Durand JB, Kantarjian H et al. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood. 2007; 110:1233-7. (Pubitemid 47281421)
52. Trent JC, Patel SS, Zhang J et al. Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate. Cancer. 2010; 116:184-92.
53. Luong BT, Chong BS, Lowder DM. Treatment options for rheumatoid arthritis: celecoxib, leflunomide etanercept, and infliximab. Ann Pharmacother. 2000; 34:743-60. (Pubitemid 30395775)
54. Wall GC, Heyneman C, Pfanner TP. Medical options for treating Crohn's disease in adults: focus on antitumor necrosis factor-α chimeric monoclonal antibody. Pharmacotherapy. 1999; 19:1138-52. (Pubitemid 29455935)
55. Wolfe F, Freundlich B, Straus WL. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol. 2003; 30:36-40. (Pubitemid 36077769)
56. Wolfe F, Mitchell DM, Sibley JT et al. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994; 37:481-94. (Pubitemid 24115934)
57. Puttini-Sarzi P, Atzeni F, Shoenfeld Y et al. TNF-α, rheumatoid arthritis, and heart failure: a rheumatological dilemma. Autoimmun Rev. 2005; 4:153-61. (Pubitemid 40488744)
58. Seta Y, Shan K, Bozkurt B et al. Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail. 1996; 2:243-9.
59. Sack MN. Tumor necrosis factor-α in cardiovascular biology and the potential role for anti-tumor necrosis factor-α therapy in heart disease. Pharmacol Ther. 2002; 94:123-35. (Pubitemid 34615962)
60. Feldman AM, Combes A, Wagner D et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol. 2000; 35:537-44. (Pubitemid 30167009)
61. Kubota T, McTiernan CF, Frye CS et al. Dilated cardiomyopathy in transgenic mice with cardiac specific overexpression of tumor necrosis factor. Circ Res. 1997; 81:627-35. (Pubitemid 27432751)
62. Enbrel (etanercept) package insert. Thousand Oaks, CA: Immunex Corporation; 2010 Sep.
63. Fichtlscherer S, Rossig L, Breuer S et al. Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure. Circulation. 2001; 104:3023-5. (Pubitemid 34014050)
64. Coletta AP, Clark AL, Banarjee P et al. Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH. Eur J Heart Fail. 2002; 4:559-61. (Pubitemid 36564977)
65. Anker SD, Coats AJ. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL, and ATTACH. Int J Cardiol. 2002; 86:123-30. (Pubitemid 35284800)
66. Remicade (infliximab) package insert. Malvern, PA: Centocor Ortho Biotech Inc.; 2010 Oct.
67. Curtis JR, Kramer JM, Martin C et al. Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-α antagonists. Rheumatology. 2007; 46:1688-93. (Pubitemid 350018491)
68. Listing J, Strangfeld A, Kekow J et al. Does tumor necrosis factor α inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum. 2008; 58:667-77. (Pubitemid 351364864)
69. Danila MI, Patkar NM, Curtis JR et al. Biologics and heart failure in rheumatoid arthritis: are we any wiser? Curr Opin Rheumatol. 2008; 20:327-33. (Pubitemid 351483324)
70. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med. 2004; 116:305-11. (Pubitemid 38230289)
71. Schlondorff D. Renal complications of nonsteroidal anti-inflammatory drugs. Kidney Int. 1993; 44:643-53. (Pubitemid 23265236)
72. Johnson AG, Seideman P, Day RO. Adverse drug interactions with nonsteroidal anti-inflammatory drugs (NSAIDs): recognition, management and avoidance. Drug Saf. 1993; 8:99-127. (Pubitemid 23075561)
73. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med. 2000; 160:777-84. (Pubitemid 30165238)
74. Feenstra J, Heerdink ER, Grobbee DE et al. Association of nonsteroidal antiinflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam Study. Arch Intern Med. 2002; 162:265-70. (Pubitemid 34127403)
75. Mamdani M, Juurlink DN, Lee DS et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet. 2004; 363:1751-6. (Pubitemid 38698377)
76. Huerta C, Varas-Lorenzo C, Castellsague J et al. Non-steroidal anti-inflammatory drugs and risk of first hospital admission for heart failure in the general population. Heart. 2006; 92:1610-5. (Pubitemid 44629166)
77. Singh SN, Fletcher RD, Fisher SG et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med. 1995; 333:77-82.
78. Torp-Pedersen C, Møller M, Bloch-Thomsen PE et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med. 1999; 341:857-65.
79. Podrid PJ, Schoeneberger A, Lown B. Congestive heart failure caused by oral disopyramide. N Engl J Med. 1980; 302:614-7.
80. Ravid S, Podrid PJ, Lampert S et al. Congestive heart failure induced by six of the newer antiarrhythmic drugs. J Am Coll Cardiol. 1989; 14:1326-30. (Pubitemid 19268687)
81. Dobrev D, Nattel S. New antiarrhythmic drugs for treatment of atrial fibrillation. Lancet. 2010; 375:1212-23.
82. Køber L, Torp-Pedersen C, McMurray JJ et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008; 358:2678-87. (Pubitemid 351860860)
83. Multaq (dronedarone) package insert. Bridgewater, NJ: Sanofi-Aventis U.S.; 2009 Jul.
84. Boumpas DT, Chrousos GP, Wilder RL et al. Glucocorticoid therapy for immunemediated diseases: basic and clinical correlates. Ann Intern Med. 1993; 119:1198-208. (Pubitemid 23361450)
85. Pensabeni-Jasper T, Panush RS. Corticosteroid usage: observations at a community hospital. Am J Med Sci. 1996; 311:234-9.
86. Souverein PC, Berard A, Van Staa TP et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart. 2004; 90:859-65. (Pubitemid 39005927)
87. Liu C, Chen H, Zhou C et al. Potent potentiating diuretic effects of prednisone in congestive heart failure. J Cardiovasc Pharmacol. 2006; 48:173-6. (Pubitemid 44691220)
88. Liu C, Liu G, Zhou C et al. Potent diuretic effects of prednisone in heart failure patients with refractory diuretic resistance. Can J Cardiol. 2007; 23:865-8. (Pubitemid 350011265)
89. Mahè I, Grenard AS, Caulin C et al. Defining the role of calcium channel antagonists in heart failure due to systolic dysfunction. Am J Cardiovasc Drugs. 2003; 3:33-41. (Pubitemid 36240413)
90. Feldman AM. Can we alter survival in patients with congestive heart failure? JAMA. 1992; 267:1956-61.
91. Packer M, Lee WH, Medina N et al. Prognostic importance of immediate hemodynamic response to nifedipine in patients with severe left ventricular dysfunction. J Am Coll Cardiol. 1987; 10:1303-11. (Pubitemid 18004684)
92. Silvestry FE, St John Sutton MG. Sustained-release calcium channel antagonists in cardiovascular disease: pharmacology and current therapeutic use. Eur Heart J. 1998; 19(suppl I):I8-14.
93. Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension: the Systolic Hypertension in Europe (Syst-Eur) trial investigators. Lancet. 1997; 350:757-64.
94. Brown MJ, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomised to double blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000; 356:366-72. (Pubitemid 30487492)
95. ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288:2981-97.
96. Packer M, O'Connor CM, Ghali JK et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med. 1996; 335:1107-14. (Pubitemid 26330964)
97. Thackray S, Witte K, Clark AL et al. Clinical trials update: OPTIME-CHF, PRAISE-2, ALLHAT. Eur J Heart Fail. 2000; 2:209-12.
98. Cohn J, Ziesche S, Smith R et al. Effect of calcium channel antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Circulation. 1997; 96:856-63. (Pubitemid 27329620)
99. Lindenfeld J, Albert NM, Boehmer JP et al. Executive summary: HFSA 2010 comprehensive heart failure practice guideline. J Card Fail. 2010; 16:475-539.
100. Sporonox (itraconazole) package insert. Raritan, NJ: Ortho-McNeil- Janssen; 2009 Mar.
101. Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole. Lancet. 2001; 357:1766-7. (Pubitemid 32524211)
102. Fung SL, Chau CH, Yew WW. Cardiovascular adverse effects during itraconazole therapy. Eur Respir J. 2008; 32:240.
103. Slørdal L, Spigset O. Heart failure induced by non-cardiac drugs. Drug Saf. 2006; 29:567-86. (Pubitemid 44175028)
104. Food and Drug Administration. Fenphen safety update information. www. fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ ucm072820.htm (accessed 2011 May 17).
105. Weissman NJ. Appetite suppressants and valvular heart disease. Am J Med Sci. 2001; 321:285-91. (Pubitemid 32275936)
106. Jollis JG, Landolfo CK, Kisslo J et al. Fenfluramine and phentermine and cardiovascular findings: effects of treatment duration on prevalence of valve abnormalities. Circulation. 2000; 101:2071-7. (Pubitemid 30233171)
107. Adipex-P (phentermine hydrochloride) package insert. Sellersville, PA: Teva; 2005 Jul.
108. Goldenberg L, So A, Fleshner N et al. The role of 5-alpha reductase inhibitors in prostate pathophysiology: is there an additional advantage to inhibition of type 1 isoenzyme? Can Urol Assoc J. 2009; 3(suppl 2):S109-14.
109. Andriole GL, Bostwick DG, Brawley OW et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010; 362:1192-202.
110. Merrill DB, Dec GW, Goff DC. Adverse cardiac effects associated with clozapine. J Clin Psychopharmacol. 2005; 25:32-41. (Pubitemid 40129380)
111. Kilian JG, Kerr K, Lawrence C et al. Myocarditis and cardiomyopathy associated with clozapine. Lancet. 1999; 354:1841-5.
112. La Grenade L, Graham D, Trontell A. Myocarditis and cardiomyopathy associated with clozapine use in the United States. N Engl J Med. 2001; 345:224-5. (Pubitemid 32662140)